Mercer Global Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$110K Sell
41,821
-66,207
-61% -$229K ﹤0.01% 3581
2026
Q2
$369K Buy
108,028
+25,480
+31% +$84.7K ﹤0.01% 2592
2026
Q1
$296K Buy
82,548
+66,502
+414% +$264K ﹤0.01% 2450
2025
Q4
$56.3K Buy
16,046
+601
+4% +$2.06K ﹤0.01% 2780
2025
Q3
$50.4K Buy
+15,445
New +$48.6K ﹤0.01% 2587

Other funds holding RCKT

Mercer Global Advisors's RCKT Position: Q3 2026 in Review

Mercer Global Advisors reduced its Rocket Pharmaceuticals (RCKT) stake by 61% in Q3 2026, selling an estimated $229K and leaving 41,821 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3581.

Mercer Global Advisors first reported a position in RCKT in Q3 2025 and has held it in 5 quarters since. The position peaked at $369K in Q2 2026. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Mercer Global Advisors held 41,821 shares of Rocket Pharmaceuticals worth $110K as of Q3 2026.
  • Mercer Global Advisors sold 66,207 Rocket Pharmaceuticals shares in Q3 2026, an estimated $229K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #3581 holding.
  • Mercer Global Advisors first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Mercer Global Advisors's Rocket Pharmaceuticals position peaked at $369K in Q2 2026.
  • 175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.